Several anti-PD-1/anti-PD-L1 mAbs are actively in clinical trials for treatment of a variety of solid tumors including non-small cell lung cancer (NSCLC) and melanoma [18-21]. Here, CD274 is linked to non-small cell lung carcinoma.